Physician profile
Ian C Gilchrist
NPI 1306804943
$13,449.56
in general payments reported to CMS, 2019-2025
25 companies · $1,263 in 2025
The $1,263 reported for 2025 was more than what 75% of Cardiovascular Disease providers received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $3,957 · 2020: $2,518 · 2021: $1,401 · 2022: $2,113 · 2023: $1,402 · 2024: $796 · 2025: $1,263.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,562 · Consulting Fee: $900.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,561.74 |
| Consulting Fee | $900.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Terumo Medical Corporation | $6,946.52 | 2019-2025 | Tr Band, Glidewire, Metacross Otw |
| Cardinal Health 200 LLC | $3,113.51 | 2019-2021 | |
| Abbott Laboratories | $1,039.25 | 2020-2025 | Optis, Cardiomems, Ultreon |
| Boston Scientific Corporation | $484.67 | 2022-2024 | Rotapro, Watchman Access System, Jetstream Sc |
| Medtronic, INC. | $349.70 | 2021-2025 | Onyx Frontier, Corevalve Evolut R, Symplicity G3 |
| E.R. Squibb & Sons, L.L.C. | $236.51 | 2022 | |
| Medtronic Vascular, INC. | $195.06 | 2019-2020 | |
| Chiesi USA, INC. | $170.23 | 2021-2023 | Cleviprex, Kengreal |
| Biotronik INC. | $127.49 | 2024 | Nhancer Rx, Recross, Trapit |
| Boehringer Ingelheim Pharmaceuticals, INC. | $125.00 | 2022 | |
| Shockwave Medical, INC | $116.26 | 2021-2023 | Shockwave Ivl System With The Shockwave C2 Coronary Ivl Catheter |
| Penumbra, INC. | $111.06 | 2023 | Indigo System |
| Teleflex LLC | $85.15 | 2023 | Guideliner |
| Cathworks, INC. | $84.12 | 2023 | Ffrangio |
| Cardiovascular Systems INC. | $59.27 | 2019 |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $44.53 | 2022 | |
| Astrazeneca Pharmaceuticals Lp | $37.89 | 2021-2022 | |
| Cook Medical LLC | $27.04 | 2019 | |
| Abiomed | $25.59 | 2023 | Impella |
| Pfizer INC. | $24.14 | 2024 | |
| Edwards Lifesciences Corporation | $20.75 | 2021 | |
| Philips North America LLC | $15.48 | 2023 | |
| Cvrx, INC. | $10.34 | 2024 | Barostim Neo System |
2 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ian Gilchrist listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.